Evidence map›Paper›PMID 37773177›Full record

ArticleNPJ Regenerative medicine2023

An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration.

Juan Antonio Romero-Torrecilla, José María Lamo-Espinosa, Purificación Ripalda-Cemboráin, Tania López-Martínez, Gloria Abizanda, Luis Riera-Álvarez, Sergio Ruiz de Galarreta-Moriones, Asier López-Barberena, Naiara Rodríguez-Flórez, Reyes Elizalde and 9 more

Open access · goldAbstract read
In one paragraph

Article in NPJ Regenerative medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 3 countries.

Juan Antonio Romero-TorrecillaCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
José María Lamo-EspinosaDepartment of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain.
Purificación Ripalda-CemboráinCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0001-8425-3563
Tania López-MartínezCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0002-0879-3995
Gloria AbizandaCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
Luis Riera-ÁlvarezDepartment of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain.
Sergio Ruiz de Galarreta-MorionesTecnun-School of Engineering, Universidad de Navarra, San Sebastian, Spain.ORCID http://orcid.org/0000-0001-8179-580X
Asier López-BarberenaTecnun-School of Engineering, Universidad de Navarra, San Sebastian, Spain.
Naiara Rodríguez-FlórezTecnun-School of Engineering, Universidad de Navarra, San Sebastian, Spain.ORCID http://orcid.org/0000-0002-5911-8113
Reyes ElizaldeTecnun-School of Engineering, Universidad de Navarra, San Sebastian, Spain.
Vineetha JayawarnaCenter for the Cellular Microenvironment, James Watt School of Engineering, University of Glasgow, Glasgow, United Kingdom.
José Valdés-FernándezCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
Miguel Echanove-González de AnleoCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
Peter ChildsDepartment of Biomedical Engineering, University of Strathclyde, Glasgow, United Kingdom.ORCID http://orcid.org/0000-0001-7603-9911
Elena de Juan-PardoT3mPLATE, Harry Perkins Institute of Medical Research, Queen Elizabeth II Medical Centre and the UWA Centre for Medical Research, The University of Western Australia, Perth, Australia.
Manuel Salmeron-SanchezCenter for the Cellular Microenvironment, James Watt School of Engineering, University of Glasgow, Glasgow, United Kingdom.
Felipe PrósperCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0001-6115-8790
Emma Muiños-LópezCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain. emuinos@unav.es.ORCID http://orcid.org/0000-0002-6618-4135
Froilán Granero-MoltóCell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain. fgranero@unav.es.ORCID http://orcid.org/0000-0003-4817-5232
Navarre Institute of Health Research · ESClinica Universidad de Navarra · ESUniversidad de Navarra · ESUniversity of Glasgow · GBIkerbasque · ESThe University of Western Australia · AUUniversity of Strathclyde · GB

Funding

Departamento de Educación, Gobierno de Navarra (Department of Education, Government of Navarra) PC009-010-011 and PC073-074-075, 3DMedicalEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 874889RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/P001114/1
6 · The paper itself

Abstract

During bone regeneration, the periosteum acts as a carrier for key regenerative cues, delivering osteochondroprogenitor cells and crucial growth factors to the injured bone. We developed a biocompatible, 3D polycaprolactone (PCL) melt electro-written membrane to act as a mimetic periosteum. Poly (ethyl acrylate) coating of the PCL membrane allowed functionalization, mediated by fibronectin and low dose recombinant human BMP-2 (rhBMP-2) (10-25 μg/ml), resulting in efficient, sustained osteoinduction in vitro. In vivo, rhBMP-2 functionalized mimetic periosteum demonstrated regenerative potential in the treatment of rat critical-size femoral defects with highly efficient healing and functional recovery (80%-93%). Mimetic periosteum has also proven to be efficient for cell delivery, as observed through the migration of transplanted periosteum-derived mesenchymal cells to the bone defect and their survival. Ultimately, mimetic periosteum demonstrated its ability to deliver key stem cells and morphogens to an injured site, exposing a therapeutic and translational potential in vivo when combined with unprecedentedly low rhBMP-2 doses.

Identifiers

PMID37773177
PMCPMC10541910
OpenAlexW4387187896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.